Ask AI
See Activity Collection
ProCE Banner Activity

APP-Led Management of HER2-, TROP2-, and B7-H3–Directed ADC Adverse Events in Solid Tumors: Practical Strategies for the Clinic

Slideset

These downloadable slides examine the mechanisms of action, clinical evidence, and distinct adverse event profiles of HER2-, TROP2-, and emerging B7-H3–directed antibody–drug conjugates (ADCs) across solid tumors, including breast cancer, non-small-cell lung cancer, gastric/gastroesophageal junction cancer, and small-cell lung cancer. Clinical trial data and prescribing information for approved and investigational ADCs are reviewed, highlighting how differences in antibody targets, linkers, payloads, and treatment regimens influence toxicity risks. Particular emphasis is placed on the prevention, early recognition, grading, and management of interstitial lung disease/pneumonitis, stomatitis, ocular toxicity, neutropenia, diarrhea, and other treatment-related adverse events. Practical strategies for advanced practice providers include baseline risk assessment, patient education, routine monitoring, supportive care, dose modifications, timely specialty referral, and multidisciplinary coordination to guide toxicity management, minimize complications, and support safe treatment delivery.

Released: November 12, 2026

Continue Activity

Share

Faculty

Kayla Freeman

Kayla Freeman, DNP, APRN, FNP-C

Breast Medical Oncology
Co-Director, Hematology/Oncology APP Fellowship Program
Emory Winship Cancer Institute
Atlanta, Georgia
Beth Sandy

Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania 

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC

Target Audience

This educational activity is intended for advanced practice providers (APPs) in oncology, including nurse practitioners, physician assistants/physician associates, clinical nurse specialists, and other HCPs who assess, educate, triage, and manage patients with solid tumors receiving ADC therapy. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate toxicity patterns associated with HER2-, TROP2-, and emerging B7-H3–directed ADCs by integrating target, payload, linker, dosing schedule, patient comorbidities, and regimen context

  • Apply CTCAE grading and agent-specific guidance to ADC-related ILD/pneumonitis, stomatitis/oral mucositis, ocular toxicity, diarrhea, neutropenia, thrombocytopenia, nausea/vomiting, fatigue, and infusion-related reactions

  • Implement APP-led monitoring and triage workflows for early toxicity detection, dose interruption, initiation of supportive care, specialty referral, rechallenge consideration, and discontinuation when clinically indicated

  • Develop patient-centered counseling and interprofessional communication plans to improve timely reporting of ADC red-flag symptoms and coordination among multidisplinary care teams

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content, drafting educational content, revising or refining educational content, and drafting assessment question(s) and/or rationale(s).  All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.